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Abstract
Background: The importance of multidrug-resistant organisms (MDRO) in Chinese hospitals is not clearly delineated.
Thus we sought to assess the prevalence of MDRO in Chinese intensive care units (ICUs).
Methods: Prospective study of inpatients admitted consecutively to eight ICUs in four Chinese cities in 2009–10.
Admission and weekly screenings were performed by using selective media for methicillin resistant Staphylococcus aureus,
extended-spectrum beta-lactamase-producing Enterobacteriaceae, Acinetobacter and Pseudomonas aeruginosa. For the
two latters, resistance to ceftazidime defined MDRO. Backward logistic regression models were designed to assess factors
independently associated with MDRO carriage on admission and MDRO acquisition within ICUs.
Results: 686 patients were included, and the MDRO prevalence rate on admission was 30.5 % (32.7 % for ESBL-positive
Enterobacteriaceae, 3.2 % for MRSA). Antibiotic treatment prior to ICU admission was independently associated with
carriage on admission (OR: 1.4) in multivariate analysis. A total of 104 patients acquired ≥1 MDRO in ICU (overall attack
rate: 23.7 %; 14.9 % for ESBL-positive Enterobacteriaceae, and 5.1 % for MRSA). The MDRO attack rate increased from
13.2 % in the first week to 82.1 % for ICU stay > 3 weeks. Duration of antibiotic exposure (OR: 1.16; 1.1–1.2) and prior
antibiotic treatment before ICU (OR: 2.1; 1.1–3.3) were associated with MDRO acquisition in multivariate analysis. The
MDRO prevalence rate on ICU discharge was 51.2 % and the global prevalence density rate 71 per 1000 hospital-days.
Conclusion: More than one out of two patients was MDRO carrier on ICU discharge in Chinese hospitals. This is the
result of the combination of a high MDRO prevalence rate on ICU admission and a high MDRO acquisition rate within
ICU.
Background
Multidrug-resistant organisms (MDRO) are a threat
throughout the world due to antibiotic overuse and cross-
transmission [1]. Infections due to MDRO increase
morbidity and even mortality among inpatients. Intensive
care units (ICU) are the wards where antibiotic resistance
and antibiotic use are the highest, and where the impact
of antibiotic resistance is the highest [2, 3]. Accordingly,
actions to limit the rise of MDRO within hospitals should
focus on ICUs. Such programs aimed at decreasing the bur-
den of multidrug resistance were developed in many coun-
tries, and have been shown to prevent cross-transmission
within hospitals [4–6]. In China, infection control teams
are in place in hospitals since 2000, but isolation precau-
tions are seldom implemented. However, it is only very
recently that policies regarding antibiotic use in hospitals
have been issued.
Data on the epidemiology of MDRO in healthcare in
Mainland China are scarce. Most of the reports are
dealing on identification of resistant mechanisms in
Gram-negative species such as extended-spectrum
beta-lactamases (ESBL), metallo-betalactamases, or OXA-
type beta-lactamases [7–11]. Few recent data report on
the epidemiology of MDRO in the country. Recently,
comparisons of the prevalence of MDR Acinetobacter
baumannii between Hong-Kong and other regions of
China showed that Hong-Kong had the lowest prevalence
[12]. A national antimicrobial resistance investigation
network (CHINET) [13, 14] has conducted multicen-
tre studies in 15 cities under the coordination of the
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Table 1 Characteristics of the patients according to the multi-drug resistant organisms (MDRO) carrier status
Characteristic Total Type of MDRO carriage
patients On admission ICU-acquired Not carrier P value*
n (%) n (%) n (%) n (%)
Total 686 (100.0) 247 (100.0) 104 (100.0) 335 (100.0)
Male (yes) 405 (59.0) 149 (60.3) 63 (60.6) 193 (57.6) 0.59
Severe/critical status on admission 525 (75.5) 192 (77.7) 87 (83.7) 246 (73.4) 0.04
Previous hospitalization 190 (27.7) 121 (49.0) 46 (44.2) 125 (37.3) 0.21
Origin of patients before ICUa
- community 28 (4.1) 12 (4.9) 5 (4.8) 11 (3.3) reference
- emergency room 115 (16.8) 40 (16.2) 30 (28.9) 45 (13.4) 1.0
- other wards 494 (72.0) 173 (70.0) 61 (58.7) 260 (77.6) 0.21
- other hospitals 30 (4.4) 13 (5.2) 6 (5.8) 11 (3.3) 0.58
- others/ no data 16 (2.3) 7 (2.8) 2 (1.9) 7 (2.1) 1.0
Invasive devices before ICU 313 (45.6) 132 (53.4) 48 (46.2) 133 (39.7) 0.24
Invasive devices in ICU 640 (93.3) 233 (94.3) 102 (98.1) 305 (91.0) 0.02
- mechanical ventilation 381 (55.5) 135 (54.7) 66 (63.5) 180 (53.7) 0.08
- indwelling urinary catheter 629 (91.7) 224 (90.7) 98 (94.2) 307 (91.6) 0.39
- intravascular catheter 514 (74.9) 200 (81.0) 88 (84.6) 226 (67.5) 0.001
Antibiotic in the last 3 months 279 (40.7) 118 (47.8) 58 (55.8) 103 (30.7) <0.001
Antibiotic on ICU admission 586 (85.6) 204 (82.6) 89 (85.6) 293 (87.7) 0.57
- > 1 drug 232 (33.8) 82 (33.2) 39 (37.5) 111 (33.1) 0.41
Antibiotic in ICU
- none 37 (5.4) 17 (6.9) 5 (4.8) 15 (4.5) reference
- 1 drug 314 (45.8) 107 (43.3) 33 (31.7) 174 (51.9) 0.34
- 2 drugs 210 (30.6) 69 (27.9) 28 (26.9) 113 (33.7) 0.56
- > 2 drugs (3–7) 125 (18.2) 54 (21.9) 38 (36.6) 33 (9.9) 0.04
- penicillins 8 (1.2) 3 (1.2) 0 5 (1.5) 0.60
- penicillins + inhibitors 192 (28.0) 72 (29.2) 46 (44.2) 74 (22.1) <0.001
- cephalosporins 1st & 2nd G 155 (22.6) 51 (20.7) 13 (12.5) 91 (27.2) 0.002
- cephalosporins 3rd G /aztreonam 223 (32.5) 79 (32.0) 40 (38.5) 104 (31.0) 0.16
- carbapenems 140 (20.4) 61 (24.7) 30 (29.9) 49 (14.6) 0.001
- aminoglycosides 13 (1.9) 4 (1.6) 4 (3.9) 5 (1.5) 0.23
- fluoroquinolones 111 (16.2) 45 (18.2) 15 (14.4) 51 (15.2) 0.84
- glycopeptides 116 (16.9) 45 (18.2) 33 (31.7) 38 (11.3) <0.001
- others 194 (28.3) 69 (27.9) 32 (30.8) 93 (27.8) 0.55
Type of discharge at 28 ICU daysb
- discharged from hospital 83 (12.1) 35 (14.2) 16 (15.4) 32 (9.6) reference
- remain in ICU 36 (5.2) 16 (6.5) 16 (15.4) 4 (1.2) 0.001
- other ward 516 (75.2) 173 (70.0) 58 (55.8) 285 (85.3) 0.01
- death 45 (6.6) 22 (8.9) 10 (9.6) 13 (3.9) 0.44
Median (range) Median (range) Median (range) Median (range)
Age (year) 66 (9–101) 65 (9–101) 66 (21–95) 67 (15–94) 0.99
Length of stay (days)
- in hospital before ICU admission 6 (0 – >60) 7 (0 – >60) 4 (0 – >60) 7 (0 – >60) 0.05
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Chinese Ministry of Health (MOH). Methicillin-resistant
Staphylococcus aureus (MRSA) have been shown to repre-
sent 62.9 % of all S. aureus isolates isolated during the
study period, and 47.5 % of Escherichia coli isolates and
29.2 % of Klebsiella pneumoniae isolates were resistant to
cefotaxime [13]. However, there are some methodological
issues. Indeed, one may question in China if patients with
the most difficult to treat diseases or with relapsing infec-
tions are not more likely to be sampled than patients
improving with a short course of empiric antibiotic regi-
men. Consequently, available data on bacterial resistance
may overestimate resistance rates.
Because of the lack of data at the country level, and
because it is of paramount importance to assess the
magnitude of antimicrobial resistance to evaluate the
current situation, and help promoting a program to curb
MDRO in China, we designed a multicentre study to
evaluate the baseline prevalence rates of MDRO in a
sample of Chinese ICUs.
Methods
Surveillance program
A surveillance and prevention program of MDRO was
designed in 2008 by the Chinese Ministry of Health with
the technical support from Assistance-Publique Hôpitaux
de Paris, France and the financial support of bioMérieux,
France. The evaluation of the burden of MDRO in ICUs
was chosen to initiate the program over a 6-month period
in 2009–2010.
All patients consecutively admitted during the study-
period to participating ICUs for a length of stay > 24 hours
were screened on admission, weekly thereafter and on
ICU discharge, for nasal carriage of MRSA and digestive
carriage of ESBL-producing Enterobacteriaceae as well as
A. baumannii or Pseudomonas aeruginosa resistant to
ceftazidime. The duration of participation varied accord-
ing to each ICU.
Bacteriology
Nasal swabs were inoculated onto ChromID MRSA and
rectal swabs onto ChromID ESBL (bioMérieux, Marcy
l’Etoile, France). All green colonies growing on ChromID
MRSA after 24 hours were considered as MRSA [15].
For each type of gram-negative bacilli isolated on the
ChromID ESBL screening media, identification and
antibiotic susceptibility testing were performed by
Vitek2 (bioMérieux, France), and isolates suspected to
produce ESBL were sent in a referral centre for ESBL
confirmation by using ESBL Etest strips (bioMérieux,
France). A. baumannii and P. aeruginosa isolates resistant
to ceftazidime were considered as MDRO.
Table 1 Characteristics of the patients according to the multi-drug resistant organisms (MDRO) carrier status (Continued)
- in ICU 4 (4 – >28) 4 (1 – >28) 10 (2 – >28) 4 (1 – >28) <0.001
- before MDR acquisition 7 (3 – >28) 0 7 (3 – >28) -
Total antibiotic-days in ICU 3 (0 –27) 5 (0–21) 3 (0–25) <0.001
*Comparing ICU-acquired MDRO patients to non carriers; aData are missing for 3 patients; bData are missing for 6 patients
Table 2 Prevalence and incidence density rates of multidrug-resistant organisms (MDRO) in 8 Chinese intensive care units (ICU) for
the 686 patients
Indicator All MDRO MRSA ESBL-E A. baumannii P. aeruginosa
Number of imported cases 247 22 224 9 4
Number of ICU-acquired cases 104 36 69 35 5
Prevalence rate on admission (n/100 admissions) 36.0 3.2 % 32.7 % 1.3 % 0.6 %
Prevalence rate on discharge (n/100 admissions) 51.2 % 8.5 % 42.7 % 6.4 % 1.3 %
Global prevalence density rate (n/1000 hospital-days) 71.1 ‰ 11.7 ‰ 59.3 ‰ 8.9 ‰ 1.8 ‰
Incidence density rate (n/1000 hospital-days) 35.0 ‰ 7.5 ‰ 21.5 ‰ 7.3 ‰ 1.0 ‰
Attack rate (n/100 admissions)
- overall 23.7 % 5.1 % 14.9 % 5.2 % 0.7 %
- ICU stay≤ 1 week 13.2 % 2.1 % 9.4 % 1.8 % 0
- 1 week < ICU stay ≤ 2 weeks 40.3 % 11.5 % 26.2 % 12.2 % 0
- 2 weeks < ICU stay≤ 3 weeks 56.5 % 19.5 % 21.4 % 15.9 % 0
- ICU stay > 3 weeks 82.1 % 13.7 % 46.7 % 11.8 % 9.6 %
MRSA methicillin-resistant Staphylococcus aureus, ESBL-E Enterobacteriaceae producing extended-spectrum beta-lactamase
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Data collection
Data were prospectively collected and included basic
demographic data on admission, previous history of
hospitalization in the last 6 months, antibiotic and inva-
sive devices use three month before and during admission.
Patients harbouring MDRO in a clinical sample were also
considered as MDRO carriers. The time to MDRO
acquisition was calculated from ICU admission to the first
MDRO-positive sample.
Analysis
Data were analysed by using Stata 11 (StataCorp, College
Station, TX). Categorical variables were compared using
the Fischer exact test, and the Mann–Whitney test was
Table 3 Prevalence and incidence density rates for all multidrug-resistant organisms (MDRO) according to the intensive care unit
(ICU)
Rate ICU identification
1 (n = 72) 2 (n = 78) 3 (n = 22) 4 (n = 132) 5 (n = 137) 6 (n = 90) 7 (n = 58) 8 (n = 97)
Number of beds 15 49 15 10 18 16 33 16
Annual number of admission 1400 3200 1200 1000 2400 2600 2200 1300
Median length of staya (range) 7.5 (2–33) 4 (2–28) 3.5 (2–17) 2 (2–28) 3 (2–38) 14 (2–29) 4 (2–22) 3 (2–28)
Number of imported cases 26 17 6 45 54 45 9 45
Number of ICU-acquired cases 19 9 1 12 19 20 7 17
Prevalence rate on admission
(n/100 admissions)
36.1 21.8 27.3 34.1 39.4 50.0 15.5 46.4
Prevalence rate on discharge
(n/100 admissions)
62.5 33.3 31.8 43.2 53.3 72.2 27.6 63.9
Attack rate (n/100 admissions) 41.3 14.8 6.3 13.8 22.9 44.4 14.3 32.7
Global prevalence density rate
(n/1000 hospital-days)
64.5 58.2 55.1 95.8 114.1 47.5 47.2 85.6
Incidence density rate (n/1000 hospital-days)a 45.8 25.4 12.3 28.8 52.1 31.4 25.2 39.9
Median time acquisition (range) 7 (3–30) 4 (3–19) 7 (−) 7 (3–28) 5 (3–8) 7 (3–24) 7 (3–7) 12 (3–28)
aLength of stay for patients included in the study
Fig. 1 Kaplan-Meier curves representing multidrug resistant (MDR) organisms acquisition in intensive care units according to the length of stay
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Table 4 Characteristics of the patients according to the carrier status of extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae
Characteristics ESBL-Enterobacteriaceae carriage
On admission ICU-acquired Not carrier P value*
n (%) n (%) n (%)
Total 224 (100.0) 69 (100.0) 393 (100.0)
Male (yes) 137 (61.2) 45 (65.2) 223 (56.7) 0.19
Severe/critical status on admission 172 (76.8) 53 (76.8) 300 (76.3) 1.0
Previous hospitalization 111 (49.6) 36 (52.2) 145 (36.9) 0.02
Origin of patients before ICUa
- community 10 (4.5) 4 (5.8) 14 (3.6) reference
- emergency room 38 (17.0) 17 (24.6) 60 (15.3) 1.0
- other wards 155 (69.2) 42 (60.9) 297 (75.6) 0.27
- other hospitals 12 (5.4) 4 (5.8) 14 (3.6) 1.0
- others/no data 7 (3.1) 2 (2.9) 7 (1.8) 1.0
Invasive devices before ICU 117 (52.2) 29 (42.0) 167 (42.5) 0.94
Invasive devices in ICU 212 (94.6) 67 (97.1) 361 (91.9) 0.12
- mechanical ventilation 119 (53.1) 41 (59.4) 221 (56.2) 0.62
- indwelling urinary catheter 202 (90.2) 64 (92.8) 363 (92.4) 0.91
- intravascular catheter 182 (81.3) 56 (81.2) 276 (70.2) 0.06
Antibiotic in the last 3 months 104 (46.4) 37 (53.6) 138 (35.1) 0.003
Antibiotic on ICU admission 185 (82.6) 59 (85.5) 342 (87.2) 0.69
- > 1 drug 72 (32.1) 23 (33.3) 137 (34.9) 0.89
Antibiotic in ICU
- none 16 (7.1) 3 (4.4) 16 (4.1) reference
- 1 drug 98 (43.8) 27 (39.1) 189 (48.1) 0.72
- 2 drugs 64 (28.6) 19 (27.5) 125 (31.8) 0.72
- > 2 drugs (3–7) 46 (20.5) 20 (29.0) 63 (16.0) 0.55
- penicillins 3 (1.3) 2 (2.9) 5 (1.3) 0.31
- penicillins + inhibitors 62 (27.7) 27 (39.1) 104 (26.5) 0.03
- cephalosporins 1st & 2nd G 45 (20.1) 7 (10.1) 103 (26.2) 0.004
- cephalosporins 3rd G /aztreonam 75 (33.5) 28 (40.6) 122 (31.0) 0.12
- carbapenems 54 (24.1) 20 (29.0) 66 (16.8) 0.02
- aminoglycosides 4 (1.8) 1 (1.5) 8 (2.0) 1.0
- fluoroquinolones 41 (18.3) 8 (11.6) 66 (16.8) 0.28
- glycopeptides 39 (17.4) 17 (24.6) 60 (15.3) 0.05
- others 159 (71.0) 17 (24.6) 117 (29.8) 0.39
Type of discharge at 28 ICU daysb
- discharged from hospital 31 (13.8) 10 (14.5) 42 (10.7) reference
- remain in ICU 16 (7.1) 10 (14.5) 10 (2.5) 0.02
- other ward 161 (71.9) 40 (58.0) 315 (80.2) 0.11
- death 15 (6.7) 5 (7.2) 25 (6.4) 1.0
Median (range) Median (range) Median (range)
Age (year) 65 (9 – 91) 64 (22–95) 67 (15–94) 0.60
Length of stay (days)
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used for continuous variables. Multivariate analysis was
performed by using logistic regression to determine
factors independently associated with ICU acquisition of
MDRO among non-carriers and factors associated with
carriage on admission. Variables with p < 0.10 in univariate
analysis were introduced in the model, and backward ana-
lysis was performed. Variables not significantly associated
with the outcome were removed based on the Wald statis-
tic. The Hosmer-Lemeshov test was used for assessing
models’ fitness. Only the most parsimonious models, i.e.
those with the least variables and the most significance, are
presented. Partially correlated variables were not introduced
simultaneously in the models. P values are two tailed, and
P <0.05 was considered statistically significant.
The prevalence rate was defined as the proportion of
patients carrying a MDRO during the 6-month study
period per 100 ICU admissions. The attack rate is a cumu-
lative incidence rate and was defined as the proportion of
patients acquiring MDRO within ICU during the study
period per 100 patients admitted within ICU and included
in the study. The incidence density rate was defined as the
proportion of patients carrying a MDRO during the study
period per 1000 hospital-days computed for patients
included in the study.
Data collected were part of standard care during the
period of the study, and were anonymysed before process-
ing. Ethical clearance was obtained locally for each of the
eight participating hospitals (Beijing:Peking Union Medical
College Hospital, Peking University People’s Hospital, Pe-
king University First Hospital, and China-Japan Friendship
Hospital; Shanghai: Zhongshan Hospital Fudan University,
and Ruijin Hospital; Changsha: Xiangya Hospital,; Guan-
dong: Nanfang Hospital).
Results
A total of 8 voluntary Chinese ICUs (5 mixed, 2 surgi-
cal, and 1 medical ICU) from four regions (4 in Beijing,
2 in Shanghai, 1 in Changsha, and 1 in Guandong)
participated anytime in the prevalence study. The
number of patients included in each ICU during the
study period varied from 22 to 137 (median, 86) for a
total of 686 patients. The overall characteristics of the 686
patients included in the study are given in Table 1. A total
of 59.0 % were male, and 75.5 % had severe or critical status
on admission. The proportion of patients with
mechanical ventilation was 55.5 %. The later propor-
tion varied from 31.4–94.9 %, three units having a pro-
portion higher than 50 %.
The global prevalence rate of MDRO on admission
among all included patients (i.e. length of stay > 24 h) was
36.0 % (Table 2). The rates varied from 15.5–50.0 %
according to the ICU, 6 out of the 8 ICUs units having
rates > 25.0 % (Table 3). The rate was the highest for
ESBL-producing Enterobacteriaceae (32.7 %), and the low-
est for P. aeruginosa (0.6 %). Among all ESBL-producing
Enterobacteriaceae isolated during the study period,
83.5 % belong to the Escherichia coli species, and 10.1 %
were Klebsiella pneumoniae. A total of 104 patients
acquired at least one of the four previously defined
MDRO during ICU stay, resulting in an overall attack rate
of 23.7 % and an incidence density rate of 35.0 per 1000
hospital-days (Table 2). The attack rates varied from
6.3–44.4 % and the incidence density rates from 12.3 to
45.8 per 1000 hospital-days according to the ICU
(Table 3). The respective attack rates for each MDRO
were 14.9 % for ESBL-positive Enterobacteriaceae,
5.4 % for MRSA, 5.2 % for A. baumannii, and 0.7 % for
P. aeruginosa (Table 2). The overall prevalence rate on
ICU discharge was 51.2 %, and the prevalence density
rate of 71.1 per 1000 hospital-days. The median time of
acquisition was 7 days for ESBL-producing Enterobac-
teriaceae, MRSA, and A. baumannii, and 14 days for
P. aeruginosa. As expected, the risk to acquire MDRO
increased with the ICU length of stay (Fig. 1). The
overall attack rate increased from 13.2 % for patients
hospitalized less than one week to 82.1 % for those
staying more than 3 weeks (Table 2).
Compared to patients with no MDRO on admission
(Table 1), those carrying at least one MDRO on admission
were more likely to have been hospitalized for a longer
period of time before ICU admission (median 7 days versus
6 days, p = 0.05), to have a prior history of invasive device
(53.4 % versus 41.2 %, p = 0.002), and to have received anti-
biotic in the last 3 months (47.8 % versus 36.7 %, p = 0.005).
In the logistic regression analysis where all three latter
variables were entered, prior history of antibiotic remained
independently associated with MDRO carriage on admis-
sion (OR: 1.4; 95 % confidence interval: 1.1–2.0).
Compared to patients who did not acquire any MDRO
during ICU (Table 1), those acquiring MDRO were more
Table 4 Characteristics of the patients according to the carrier status of extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae
(Continued)
- in hospital before ICU admission 7 (0 – >60) 5 (0 – >60) 6 (0 – >60) 0.77
- in ICU 4 (1 – >28) 8 (2 – >28) 4 (1 – >28) <0.001
- before MDR acquisition – 7 (3–28) –
Total antibiotic-days in ICU 3 (0–28) 4 (0–19) 3 (0–25) <0.001
*Comparing ICU-acquired MDRO patients to non carriers; aData are missing for 3 patients; bData are missing for 6 patients
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Table 5 Characteristics of the patients according to the carrier status of methicillin-resistant Staphylococcus aureus (MRSA)
Characteristics MRSA carriage
On admission ICU-acquired Not carrier P value*
n (%) n (%) n (%)
Total 23 (100.0) 35 (100.0) 628 (100.0)
Male (yes) 12 (52.2) 21 (60.0) 372 (59.3) 0.93
Severe/critical status on admission 19 (82.6) 30 (85.7) 476 (75.8) 0.22
Previous hospitalization 11 (47.8) 11 (31.4) 168 (26.8) 0.54
Origin of patients before ICUa
- community 2 (8.7) 1 (2.9) 25 (4.0) reference
- emergency room 2 (8.7) 13 (37.1) 100 (16.0) 0.47
- other wards 17 (73.9) 18 (51.4) 459 (73.1) 1.00
- other hospitals 2 (8.7) 3 (8.6) 25 (4.0) 0.61
- others/no data 0 0 16 (2.6) 1.00
Invasive devices before ICU 16 (69.6) 14 (40.0) 283 (45.1) 0.56
Invasive devices in ICU 22 (95.7) 34 (97.1) 599 (95.4) 1.00
- mechanical ventilation 17 (73.9) 21 (60.0) 343 (54.6) 0.53
- indwelling urinary catheter 21 (91.3) 33 (94.3) 575 (91.6) 0.76
- intravascular catheter 17 (73.9) 32 (91.4) 465 (74.0) 0.03
Antibiotic in the last 3 months 16 (69.6) 23 (65.7) 240 (38.2) 0.001
Antibiotic on ICU admission 18 (78.3) 31 (88.6) 537 (85.7) 0.81
- > 1 drug 5 (21.7) 16 (45.7) 211 (33.6) 0.21
Antibiotic in ICU
- none 2 (9.1) 0 32 (5.1) reference
- 1 drug 10 (43.5) 10 (28.6) 294 (46.8) 0.61
- 2 drugs 4 (17.4) 7 (20.0) 195 (31.1) 0.60
- > 2 drugs (3–7) 7 (30.0) 18 (51.4) 107 (17.0) 0.03
- penicillins 0 0 10 (1.6) 1.00
- penicillins + inhibitors 8 (34.8) 15 (42.9) 172 (27.4) 0.05
- cephalosporins 1st & 2nd G 3 (13.4) 5 (14.3) 146 (23.3) 0.30
- cephalosporins 3rd G /aztreonam 5 (21.7) 15 (42.9) 205 (32.6) 0.21
- carbapenems 8 (34.8) 16 (45.7) 121 (19.3) <0.001
- aminoglycosides 0 1 (2.9) 11 (1.8) 0.48
- fluoroquinolones 6 (26.1) 8 (22.9) 102 (16.2) 0.30
- glycopeptides 4 (17.4) 15 (42.9) 98 (15.6) <0.001
- others 6 (26.1) 10 (28.6) 182 (29.0) 0.96
Type of discharge at 28 ICU daysb
- discharged from hospital 3 (13.6) 8 (22.9) 71 (11.3) reference
- remain in ICU 2 (9.1) 6 (17.1) 28 (4.5) 0.27
- other ward 11 (50.0) 18 (51.4) 488 (77.7) 0.008
- death 6 (27.3) 3 (8.6) 36 (5.7) 1.00
Age (year) 71 (40–93) 70 (20–99) 65 (9–95) 0.11
Length of stay (days)
- in hospital before ICU admission 14 (0 – >60) 3 (0 – >60) 6 (0 – >60) 0.12
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likely to have an intravenous catheter before MDRO
acquisition (84.6 % versus 67.5 %, p = 0.001), to have
received antibiotic in the last 3 months (55.8 % versus
30.7 %, p < 0.001), and to receive > 2 antibiotics in ICU
(36.6 % versus 9.9 %, p = 0.04). Finally, patients with
MDRO acquisition had a longer length of stay in ICU than
those without MDRO (10 days versus 4 days, p < 0.001). In
the final model of the logistic regression analysis, only dur-
ation of antibiotic exposure (OR: 1.16 for each additional
day; 1.1–1.2) and prior antibiotic treatment before ICU
admission (OR: 2.1; 1.3–3.3) remained significantly associ-
ated with MDRO acquisition. Other variables including
severity status, presence of invasive devices, length of stay
before ICU admission or within ICU did not remain signifi-
cantly associated with MDRO acquisition.
In univariate analysis, factors associated with acquisition
of either ESBL-producing Enterobacteriaceae (Table 4), or
MRSA (Table 5), were comparable to those of any MDRO
acquisition. Receiving a glycopeptide before MRSA acqui-
sition was associated with a higher risk of MRSA
acquisition (42.9 % versus 15.6 %, p < 0.001).
When considering MDR A. baumannii acquisition
(data not shown), carriers were more likely than non-
carriers to have had invasive devices before ICU admis-
sion (75.8 % versus 43.8 %, p < 0.001), and to have
mechanical ventilation (84.9 % versus 53.6 %, p < 0.001).
A separate analysis regarding MDR P. aeruginosa ac-
quisition was not performed because of the low acquisi-
tion rate.
Discussion
We conducted the first multicentre study on MDRO
carriage in Chinese ICUs where systematic admission
screening was not a general policy. We showed that
almost one third of the patients carried MDRO on
admission and that ESBL-producing Enterobacteriaceae
were the most prevalent. There was a high incidence
density rate (35 per 1000 hospital-days) resulting in one out
of two patients carrying at least one MDRO on ICU
discharge. MRSA incidence density rate was one third that
of ESBL-producing Enterobacteriaceae. MDRO acquisition
was significantly linked to the use of antibiotics.
The present study relied on systematic screening to assess
the burden of MDRO in Chinese ICUs, as recommended
in many countries [6, 16]. It has the advantage to identify
asymptomatic carriers who are nevertheless disseminators.
In our study, the overall MDRO carriage on ICU admission
was rather elevated. The proportion of MRSA carriers on
admission in our study (3.4 %) was slightly lower than in
French ICUs at the end of the 1990s (4.2–6.9 %) [17, 18].
In studies conducted in western countries in the era of
CTX-M ESBL-positive Enterobacteriaceae, carriage of
such isolates was lower (2 % to 8 %) than in the present
study [2, 19]. Nevertheless, the rate observed in Chinese
ICUs is lower than the 60 % reported in an Indian ICU in
2008–2009 [20]. The high rate of MDRO carriers is likely
to be a combination of poor hygiene and high antibiotic
use before admission as demonstrated by the fact that, in
our study, prior antibiotic exposure was independently as-
sociated with MDRO carriage. Cross-transmission may
have occurred either in the community or within other
wards before ICU admission [21]. However, no data are
available to assess cross-transmission outside ICU in
China, and data regarding the prevalence of MDRO in the
community are also lacking.
The overall rate of MDRO acquisition was high. It
ranged from 1 per 1000 patients-days for multiresistant
P. aeruginosa to 21.5 per 1000 patients-days for ESBL-
producing Enterobacteriaceae. The latter incidence rate
is to be compared to those reported in France (1.6 to
5.3 per 1000 patients-days), or the Netherlands (14 per
1000 patients-days) [22, 23]. Incidence rates cannot be
confronted to proportions of MDRO within each spe-
cies, because the first relate mostly on carriage while
the latters are only based on clinical samples. Incidence
density data are drastically needed because it is a better
estimate of the burden of MDRO as compared to propor-
tions of resistant isolates within the species. However, the
reported proportion of ESBL-producing isolates amongst E.
coli and K. pneumonia isolated in clinical samples in China
(56.2 % and 43.6 %, respectively) [13] is far higher than the
same proportions reported in France (8 % and 13 %, re-
spectively) or in the Netherlands (4 % and 6 %, respectively)
[22, 23]. Therefore, findings of higher incidence density
rates in China as compared to other countries are con-
cordant with MDRO proportions reported elsewhere. Of
interest, the median time of acquisition reported for
ESBL-producing Enterobacteriaceae (7 days) was similar
to the one reported in France where the incidence density
rate is much lower [3]. We found that antibiotic exposure
was an independent risk factor for MDRO acquisition. No
antibiotic policy was implemented at the time of the study
Table 5 Characteristics of the patients according to the carrier status of methicillin-resistant Staphylococcus aureus (MRSA)
(Continued)
- in ICU 7 (2 – >28) 12 (3–28) 4 (1 – >28) <0.001
- before MDR acquisition – 7 (3–27) –
Total antibiotic-days in ICU 6 (0–26) 6 (2–22) 3 (0–28) <0.001
*Comparing ICU-acquired MDRO patients to non carriers; aData are missing for 3 patients; bData are missing for 6 patients
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in participating ICUs as well as in most Chinese facilities.
Moreover, data on antibiotic use in Chinese ICUs are miss-
ing preventing any benchmarking. Poor hygiene is likely to
play a major role in MDRO cross-transmission within
ICUs in addition to antibiotic exposure. However, because
the present study was not designed to assess factors in-
volved in cross-transmission, we did not collect factors
known to be linked to acquisition such as hand hygiene or
isolation precautions compliance, colonisation pressure,
nurse-to-patient ratio, case-mix, and intensity of care. Of
note, isolation precautions were not systematically imple-
mented for MDRO carriers in participating ICUs.
Our study was not designed to assess carriage of P.
aeruginosa or A. baumannii outside the digestive tract,
although it has been demonstrated that both species are
colonizing other sites [24]. It was considered that results
from this first study would help to decide if more
focused studies are needed. Therefore, rates reported
herein are likely to represent the lower part of a range.
However, the acquisition rate reported herein for A.
baumannii is similar to that reported in Italy during an
outbreak and should therefore be considered as worri-
some [25]. Similarly, this study did not look for MRSA
carriage outside anterior nares. Therefore MRSA rates
reported in our study are likely to be slightly underesti-
mated. Another weakness of our study is that we are
not reporting the genetic mechanisms of resistance of
MDRO. Although it is of interest to evaluate genes cir-
culation around the country, it has not been demon-
strated to be of any interest neither in the evaluation of
the magnitude of the bacterial resistance issue nor in
public health decision-making. Such data related to
China may be found in other studies dedicated to this
topic [7–10].
Conclusion
The present study allowed evaluating the burden of
MDRO in Chinese ICUs. We showed that antibiotic re-
sistance is of concern in ICUs but also outside the ICU
and mainly involved ESBL-positive Enterobacteriaceae.
Our study is intended to be a baseline study to be re-
peated after implementation of control measures such as
improving hygiene and mastering antibiotic use. Since
our study, a new policy for antibiotic control was issued
in China. This comprehensive policy includes restriction
of antibiotic use, strengthening of laboratory diagnosis
for bacterial resistance, antibiotic stewardship and build-
ing of regional surveillance networks. The effect of such
a policy on MDRO rates could be evaluated by using a
similar surveillance program.
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